[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642449":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":61,"collaborators":24,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":24,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Volunteer","EXPERIMENTAL","Healthy volunteers will undergo a single injection of \\[18F\\]-FTHA (a long-chain fatty acid positron emitting radiotracer) followed by up to 4 PET\u002FCT scans.",[13],"Diagnostic Test: [18F]FTHA PET\u002FCT scan",{"label":15,"type":10,"description":16,"interventionNames":17},"TD-Venous Obstruction patients","Patients with known or suspected obstruction of the thoracic duct (TD)-venous junction will undergo a single injection of \\[18F\\]-FTHA (a long-chain fatty acid positron emitting radiotracer) followed by up to 4 PET\u002FCT scans. If the patient undergoes a clinical surgical procedure then they will be asked to undergo a second \\[18F\\]FTHA PET\u002FCt scan following the same procedure as the baseline scan.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","[18F]FTHA PET\u002FCT scan","Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) scans",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Erin K Schubert, BA","CONTACT","2155736569","erin.schubert@pennmedicine.upenn.edu",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"Mary Hansbury, BS","215-746-8192","mary.hansbury@pennmedicine.upenn.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Pennsylvania Hospital","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-75.16362,39.95238,{"lat":48,"lon":47},[51,55,58],{"name":52,"role":28,"phone":53,"phoneExt":24,"email":54},"Erin Schubert","215-573-6569","erinschu@pennmedicine.upenn.edu",{"name":56,"role":57,"phone":24,"phoneExt":24,"email":24},"Paco Bravo, MD","PRINCIPAL_INVESTIGATOR",{"name":59,"role":60,"phone":24,"phoneExt":24,"email":24},"Maxim Itkin, MD","SUB_INVESTIGATOR",{"type":57,"investigatorFullName":56,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Associate Professor of Radiology","100642449","early-phase-1-18f-ftha-imaging-of-the-intestinal-and-central-lymphatic-system-100642449",false,"NCT07645573","18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","INVESTIGATION OF A POSITRON-EMITTING LONG-CHAIN FATTY ACID (18F-FTHA), FOR IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","FTHA","Inclusion Criteria:\n\nInclusion Criteria (Healthy Volunteer Cohort)\n\n1. Male and female participants will be ≥ 18 years of age.\n2. \"Healthy Volunteer\" is defined for the purposes of this study as a volunteer who is in good general health in the opinion of an investigator (some well controlled chronic medical conditions may be allowed at the discretion of an investigator if they do not believe they will interfere with the collection of imaging data, specific excluded medical conditions are listed under exclusion criteria).\n3. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nInclusion (Patient with suspected TD-venous junction obstruction cohort)\n\n1. Male and female participants will be ≥ 18 years of age\n2. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n3. Patient with chronic abdominal pain, ascites protein losing enteropathy, as well edema, with clinically suspected obstruction of the TD-venous junction and who are candidates for TD-venous junction plasty and or TD-Venous bypass\n\nExclusion Criteria:\n\nExclusion Criteria that apply to Healthy Volunteers only\n\n1. Currently taking medication for cardiac disease, hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, and\u002For history of cardiac surgery per medical record review and\u002For self-report\n2. Known history of liver or kidney disease per medical record review and\u002For self-report\n\nExclusion Criteria that applies to Healthy Volunteers and Patients:\n\n1. Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential on the day of each of the PET\u002FCT scans.\n2. Subjects who report claustrophobia or Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Self-reported difficulty with swallowing pills or allergy to components of Ensure Plus\n4. Patients with a history of medical illness or disorder that in the opinion of an investigator and\u002For study physician could compromise patient safety or interfere with the collection of imaging data, or ability to complete the study and procedures, will be excluded.\n\nParticipant may not be involved in any other research studies involving ionizing radiation conducted within 1 year of their participation of this study.",true,"ALL","18 Years",{"count":75,"type":76},25,"ESTIMATED","INTERVENTIONAL",[79],"EARLY_PHASE1","The project will be performed over a period of approximately two years. In the first year the \\[18F\\]FTHA tracer will be developed, optimized, and tested on normal volunteers. During the second year, the tracer will be investigated on patients with suspected obstruction of the thoracic duct (TD).",[82],"Lymphatic Obstruction",[84],"thoracic duct","2026-06-08",{"date":87,"type":88},"2026-06-12","ACTUAL",{"date":90,"type":88},"2025-10-10",{"date":92,"type":76},"2029-06-30",{"name":5,"class":6},1]